CoQ10
Coenzyme Q10 (ubiquinone and ubiquinol)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Coenzyme Q10, Ubiquinone, Ubiquinol, Ubidecarenone
One genuinely strong randomised outcome trial, in moderate to severe heart failure, where it cut major events from 26% to 15%. And a clean null for statin muscle pain, which is why most people take it.
Overview
CoQ10 has an unusual evidence shape: strong where almost nobody takes it, and null where almost everybody does.
The strong result is Q-SYMBIO, which randomised 420 patients with moderate to severe chronic heart failure on standard therapy to 100 mg three times daily or placebo for two years. Major adverse cardiovascular events occurred in 15% on CoQ10 against 26% on placebo, a hazard ratio of 0.50, and all-cause mortality was 10% against 18%. That is a real outcome trial with a real result.
The null is statin-associated muscle pain, which is the single most common reason people are handed a CoQ10 bottle. Seven randomised trials in 321 patients pooled to nothing, and it did not help people stay on their statin either.
There is no outcome trial of CoQ10 in healthy adults taking it for longevity.
Mechanism of action
Coenzyme Q10 is an endogenous lipid-soluble electron carrier in the mitochondrial inner membrane, shuttling electrons from complexes I and II to complex III in the respiratory chain. In its reduced form, ubiquinol, it is also a lipid-phase antioxidant that regenerates vitamin E. Statins inhibit HMG-CoA reductase, which sits upstream of both cholesterol and CoQ10 synthesis in the mevalonate pathway, and that shared pathway is the mechanistic rationale for the statin myalgia hypothesis. The rationale is sound and the trials still came back null, which is a useful reminder that a coherent mechanism is not a result.
Human evidence
One strong randomised outcome trial in a specific sick population, and a clean randomised null for the most common consumer use. Nothing in healthy adults with an outcome endpoint.
- Q-SYMBIO: 420 patients with diagnosed moderate to severe heart failure on standard therapy. Major adverse cardiovascular events 15% against 26%, hazard ratio 0.50. All-cause mortality 10% against 18%.
- Note the timing inside that trial: the 16-week endpoints were null and the benefit appeared only in the two-year outcome data. A short trial of this compound would have called it a failure.
- Statin myalgia: 7 trials, 321 patients, pooled weighted mean difference minus 0.42 with a confidence interval crossing zero. No effect on symptoms and none on staying on the statin.
- Blood pressure and migraine have smaller randomised literatures with mixed results; neither carries an outcome trial.
- Ubiquinol, the reduced form, is marketed as substantially better absorbed. There is no randomised trial comparing ubiquinol to ubiquinone on a clinical outcome.
What this does not tell you: Q-SYMBIO's population is the boundary of what it establishes: 420 people with diagnosed moderate to severe heart failure, already on standard therapy, over two years. It does not show that CoQ10 helps a healthy person, and it does not show that it helps someone with mild disease. It is also a single trial of moderate size, and the larger literature in heart failure is less consistent than that one result. For the statin myalgia null, a pooled null can hide individual responders, and the trials were small.
Reading the research record
CoQ10 is a good test of whether a site will follow its own rule. This one initially carried the owner's view that CoQ10 is close to universally worth taking, which is a common position in longevity circles. He withdrew it when the evidence was laid out, and the withdrawal is worth recording rather than quietly editing away, because the reasoning generalises.
The randomised support is one trial in 420 people with diagnosed moderate to severe heart failure on standard therapy. That trial's own sixteen-week endpoints were null, and the benefit appeared only at two years. Meanwhile the mechanistic story that made CoQ10 famous, that statins deplete it and supplementing fixes the muscle pain, has been tested seven times in 321 patients and pooled to nothing. A coherent mechanism plus a strong result in a sick population is not evidence about a healthy one. CoQ10 now appears on this site as an item tied to a diagnosis, which is what the evidence supports.
The evidence, charted
Fig. 1 · evidence composition
1of 2 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2014 and 2020.
Too few distinct publication years on this page to plot as a timeline. The newest citation on file is from 2020, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2014
The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO, a randomized double-blind trial
420 patients with moderate to severe chronic heart failure, 100 mg three times daily, two years. Major adverse cardiovascular events 15% against 26%, hazard ratio 0.50 (95% CI 0.32 to 0.80, p = 0.003). Cardiovascular mortality 9% against 16% (p = 0.026) and all-cause mortality 10% against 18% (p = 0.018). The short-term 16-week endpoints were null.
JACC Heart Failure - Review2020
Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis
7 randomised placebo-controlled trials, 321 patients with statin-associated myalgia. No benefit on muscle symptoms, weighted mean difference minus 0.42 (95% CI minus 1.47 to 0.62), and no improvement in the proportion who stayed on their statin (RR 0.99). Only 2 of 8 reviewed studies were individually positive. Trials ranged from 37 to 76 participants.
Atherosclerosis
Frequently asked questions
Does CoQ10 help with statin muscle pain?
Seven randomised trials in 321 patients say no. The pooled weighted mean difference was minus 0.42 with a confidence interval crossing zero, and it did not help people stay on their statin. The mechanism is plausible, because statins inhibit an enzyme upstream of CoQ10 synthesis, and the trials still came back null.
Should a healthy person take it?
There is no outcome trial that answers this. The strong result is in 420 people with diagnosed moderate to severe heart failure, and the most common reason healthy people are handed a bottle, statin muscle pain, has been tested seven times and pooled to nothing. On this site CoQ10 is listed as tied to a diagnosis rather than as something everyone should take.
Ubiquinol or ubiquinone?
Ubiquinol is the reduced form and is marketed as better absorbed, which pharmacokinetic data partly support. No randomised trial has compared the two forms on any clinical outcome, so the price difference buys a plausible absorption advantage rather than a demonstrated better result. Q-SYMBIO, the trial everyone cites, used ubiquinone.
Does it matter how I take it?
Yes. Absorption is poor and strongly fat-dependent, so take it with a meal containing fat. The Q-SYMBIO dose was 100 mg three times a day, which is higher than many consumer products provide in total.